TR201912451A2 - Küçük hücreli̇ dişi akci̇ğer kanseri̇nde kannabi̇noi̇d 1 reseptör agoni̇sti̇ araşi̇doni̇lsi̇klopropi̇lami̇d (acpa) - Google Patents

Küçük hücreli̇ dişi akci̇ğer kanseri̇nde kannabi̇noi̇d 1 reseptör agoni̇sti̇ araşi̇doni̇lsi̇klopropi̇lami̇d (acpa)

Info

Publication number
TR201912451A2
TR201912451A2 TR2019/12451A TR201912451A TR201912451A2 TR 201912451 A2 TR201912451 A2 TR 201912451A2 TR 2019/12451 A TR2019/12451 A TR 2019/12451A TR 201912451 A TR201912451 A TR 201912451A TR 201912451 A2 TR201912451 A2 TR 201912451A2
Authority
TR
Turkey
Prior art keywords
acpa
cannabinoid
small cell
cell lung
lung cancer
Prior art date
Application number
TR2019/12451A
Other languages
English (en)
Inventor
Nemutlu Emi̇rhan
Varan Cem
Bi̇lensoy Erem
Bi̇lgi̇ç Eli̇f
Korkusuz Petek
Boyacioğlu Özge
Original Assignee
Atilim Ueniversitesi
Hacettepe Ueniversitesi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atilim Ueniversitesi, Hacettepe Ueniversitesi filed Critical Atilim Ueniversitesi
Priority to TR2019/12451A priority Critical patent/TR201912451A2/tr
Priority to US17/617,008 priority patent/US20220168245A1/en
Priority to PCT/TR2020/050618 priority patent/WO2021034289A1/en
Publication of TR201912451A2 publication Critical patent/TR201912451A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Buluş, sentetik kannabinoid agonisti Araşidonilsiklopropilamid (ACPA) ile ilk kez küçük hücreli dışı akciğer adenokarsinomunun kannabinoid reseptörü aracılı yolak üzerinden hedeflenmesi ile ilgilidir. Buluş ile, ACPA'nın farklı dozlarda in vitro ortamda kannabinoid (CB) reseptörlerini eksprese ettiği bilinen küçük hücreli dışı akciğer kanseri hatları üzerindeki antiproliferatif etkisi ve etkili doz tespitinin yapılmış, CB1 reseptör agonisti ACPA'nın stabilitesi ve uzun süreli sabit salımını sağlayabilecek nanobiyomühendislik temelli ACPA-PCL nanopartiküler salım sistemi geliştirilmiştir.
TR2019/12451A 2019-08-20 2019-08-20 Küçük hücreli̇ dişi akci̇ğer kanseri̇nde kannabi̇noi̇d 1 reseptör agoni̇sti̇ araşi̇doni̇lsi̇klopropi̇lami̇d (acpa) TR201912451A2 (tr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
TR2019/12451A TR201912451A2 (tr) 2019-08-20 2019-08-20 Küçük hücreli̇ dişi akci̇ğer kanseri̇nde kannabi̇noi̇d 1 reseptör agoni̇sti̇ araşi̇doni̇lsi̇klopropi̇lami̇d (acpa)
US17/617,008 US20220168245A1 (en) 2019-08-20 2020-07-13 Use of cannabinoid 1 receptor agonist arachidonoyl cyclopropylamide (acpa) in non small cell lung cancer
PCT/TR2020/050618 WO2021034289A1 (en) 2019-08-20 2020-07-13 Use of cannabinoid 1 receptor agonist arachidonoyl cyclopropylamide (acpa) in non small cell lung cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2019/12451A TR201912451A2 (tr) 2019-08-20 2019-08-20 Küçük hücreli̇ dişi akci̇ğer kanseri̇nde kannabi̇noi̇d 1 reseptör agoni̇sti̇ araşi̇doni̇lsi̇klopropi̇lami̇d (acpa)

Publications (1)

Publication Number Publication Date
TR201912451A2 true TR201912451A2 (tr) 2021-03-22

Family

ID=74660248

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/12451A TR201912451A2 (tr) 2019-08-20 2019-08-20 Küçük hücreli̇ dişi akci̇ğer kanseri̇nde kannabi̇noi̇d 1 reseptör agoni̇sti̇ araşi̇doni̇lsi̇klopropi̇lami̇d (acpa)

Country Status (3)

Country Link
US (1) US20220168245A1 (tr)
TR (1) TR201912451A2 (tr)
WO (1) WO2021034289A1 (tr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3056405C (en) * 2009-05-04 2021-11-09 Bengurion University Of The Negev Research And De Nano-sized particles comprising multi-headed amphiphiles for targeted drug delivery
US8629177B2 (en) * 2010-08-24 2014-01-14 Aphios Corporation Nanoencapsulated delta-9-tetrahydrocannabinol
CA3089686A1 (en) * 2015-03-10 2016-09-15 Nanosphere Health Sciences, Llc A nanoparticle drug delivery comprising liquid lipids and cannabinoids encapsulated in a single layer of essential phospholipids
CN107837399A (zh) * 2017-10-18 2018-03-27 圆容生物医药无锡有限公司 一种双组分纳米仿生释药载体

Also Published As

Publication number Publication date
US20220168245A1 (en) 2022-06-02
WO2021034289A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
MX2023000677A (es) Compuestos moduladores de receptor de estrogeno.
BR112019022495A2 (pt) Conjugados de anticorpo que compreendem agonista de receptor similar a toll e terapias de combinação
BR112023002895A2 (pt) Anticorpos anti-ror1 e proteínas de ligação biespecíficas relacionadas
BRPI0507148A (pt) filtragem no tempo para mitigação de retardo em excesso em sistemas ofdm
Zhao The Sylvester Equation and Integrable Equations: The Ablowitz—Kaup—Newell—Segur System
BR112022006782A2 (pt) Receptores de citocina quiméricos
BR112016002405A2 (pt) método de controle de potência para canal de enlace ascendente, equipamento de usuário e sistema de comunicação
BR112017002865A2 (pt) películas compósitas à base de polietileno e artigos feitos da mesma
AR116048A1 (es) Composiciones y métodos para reprogramar receptores de células t (tcr) usando proteínas de fusión
BR112022009146A2 (pt) Técnicas para fornecer um fluxo de conteúdo baseado em um fluxo de conteúdo entregue
MX2023001571A (es) Terapia combinada con antagonistas del receptor de adenosina.
AR116321A1 (es) Películas fundidas que comprenden polímeros bimodales a base de etileno que tienen fracciones de alta densidad y alto peso molecular
Septiana An Analysis of Lexical and Contextual Meanings in Christina Perri’s Song Lyrics
Nguyen et al. Epidermal growth factor receptor signaling in precancerous keratinocytes promotes neighboring head and neck cancer squamous cell carcinoma cancer stem cell‐like properties and phosphoinositide 3‐kinase inhibitor insensitivity
BR112017014790A2 (pt) material fumável para inclusão em um artigo de fumar, método para obter material fumável, artigo de fumar e uso de uma solução de goma de acácia
Krupat Changed Forever
Altraja et al. C33 CYTOKINES AND ASTHMA MEDIATORS: Increased Expression Of The P2y12 Receptor On Human Bronchial Epithelial Cells By Leukotriene E4 Is Down-Regulated By Montelukast But Not By Ticagrelor
Lee et al. A comparison between deep and shallow stress fields in Korea using earthquake focal mechanism inversions and hydraulic fracturing stress measurements
QIN et al. Inhibitory effect of lentivirus targeting interference Cx26 on proliferation and migration of human highly metastatic hepatocellular carcinoma HCCLM3 cells
Agarwal et al. Novel Role of Raft-Associated Smoothened (SMO) in AKT Signal Regulation in Diffuse Large B Cell Lymphoma
김재현 Functional analysis of NEGR1 interacting with LIFR
上野卓教 The Sirtuin Inhibitor Tenovin-6 Upregulates Death Receptor 5 and Enhances Cytotoxic Effects of 5-Fluorouracil and Oxaliplatin in Colon Cancer Cells
LIU et al. Atractylenolide I regulates proliferation and invasion of lung cancer A549 cells through the TLR4/MyD88 pathway
Ryan Louis XIV contre Innocent XI. Les appels au futur concile de 1688 et l'opinion francaise.(Jean Orcibal)(Book Review)
Vinson The Role of the Notch-3 Receptor in Stemness, EMT, and Tumorigenesis in Colorectal Cancer